Daptomycin + Vancomycin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Staphylococcal Skin Infections
Conditions
Staphylococcal Skin Infections
Trial Timeline
Sep 9, 2011 → Oct 5, 2012
NCT ID
NCT01419184About Daptomycin + Vancomycin
Daptomycin + Vancomycin is a approved stage product being developed by Merck for Staphylococcal Skin Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01419184. Target conditions include Staphylococcal Skin Infections.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01419184 | Approved | Completed |
| NCT01196169 | Approved | Terminated |
| NCT01175707 | Approved | Terminated |
| NCT00695903 | Phase 2 | Terminated |
| NCT00426933 | Phase 2 | Completed |
| NCT00295178 | Approved | Completed |
Competing Products
20 competing products in Staphylococcal Skin Infections